FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to therapy and cardiology. Presented is a method for predicting the risk of developing life-threatening complications in the patients suffering acute myocardial infarction. For prediction of cardiogenic shock or pulmonary oedema in patients with acute myocardial infarction, plasma levels of fractalkine, asymmetric dimethylarginine and transferrin are measured by enzyme immunoassay. Formula is used to calculate the probability of developing cardiogenic shock or pulmonary oedema. If p < 0.5, a low risk of developing cardiogenic shock or pulmonary oedema is predicted. If p ≥ 0.5, a high risk of developing cardiogenic shock or pulmonary oedema is predicted.
EFFECT: invention provides combined prediction of development of such life-threatening complications as pulmonary oedema and cardiogenic shock in patients with acute myocardial infarction, regardless of comorbidity.
1 cl, 3 ex
